GI Dynamics, Inc.

Equities

GIDYL

AU000000GID7

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-99.33%

06-04	Morphic Medical Inc. Receives Approval from the U.S. Food and Drug Administration for Amendments to Certain Requirements for Its Pivotal Study	CI
2023	GI Dynamics, Inc. Announces First Patient Enrolled in the I-STEP Clinical Study of EndoBarrier in India	CI

GI Dynamics, Inc. Appoints Oern Stuge to the Board of Directors

January 04, 2017 at 09:59 pm

GI Dynamics, Inc. announced the appointment of veteran medical device executive Oern Stuge, M.D., MBA, to the company's board of directors, effective immediately. Concurrent with the appointment of Dr. Stuge, the Board of Directors of GI Dynamics has accepted the resignation of Jack Meyer, former chairman of the company. Dr. Stuge has held executive and board positions in numerous medical device companies over the past 30 years.

Latest news about GI Dynamics, Inc.

Morphic Medical Inc. Receives Approval from the U.S. Food and Drug Administration for Amendments to Certain Requirements for Its Pivotal Study	06-04	CI
GI Dynamics, Inc. Announces First Patient Enrolled in the I-STEP Clinical Study of EndoBarrier in India	13/02/23	CI
GI Dynamics, Inc. Announces Final Data from the ENDO Trial, Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity	15/06/22	CI
GI Dynamics Inc. Announces Approval of the I-STEP Clinical Study in India	31/01/22	CI
Gi Dynamics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	07/05/21	CI
Gi Dynamics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	12/03/21	CI
GI Dynamics, Inc. Auditor Raises 'Going Concern' Doubt	11/03/21	CI
GI Dynamics, Inc. Announces Termination of Charles Carter as Treasurer and Secretary	15/01/21	CI
GI Dynamics, Inc. Announces Termination of Charles Carter as Chief Financial Officer	15/01/21	CI
Gi Dynamics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	10/11/20	CI
GI Dynamics, Inc. Announces CEO Changes	06/11/20	CI
GI Dynamics, Inc. Announces Management Changes	06/11/20	CI
GI Dynamics, Inc. Announces Executive Changes	26/10/20	CI
GI Dynamics, Inc. Announces the Appointment of Joseph Virgilio as its Chief Operating Officer	15/10/20	CI
Transcript : GI Dynamics, Inc. - Shareholder/Analyst Call	03/09/20
GI Dynamics, Inc. Announces Board Resignations	10/08/20	CI
Gi Dynamics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	07/08/20	CI
GI Dynamics, Inc. announced that it has received $0.5 million in funding from Crystal Amber Asset Management Limited	03/08/20	CI
GI Dynamics, Inc. announced that it expects to receive funding from Crystal Amber Asset Management Limited	02/08/20	CI
GI Dynamics, Inc. announced that it expects to receive $9.25 million in funding from Crystal Amber Asset Management Limited	19/07/20	CI
Transcript : GI Dynamics, Inc. - Shareholder/Analyst Call	20/06/20
GI Dynamics, Inc. announced that it has received $0.75 million in funding from Crystal Amber Asset Management Limited	17/06/20	CI
Gi Dynamics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	06/05/20	CI
GI Dynamics, Inc. Enters into Sixth Amendment to the Senior Secured Convertible Promissory Note	31/03/20	CI
GI Dynamics, Inc. Announces Change to Board of Directors	30/03/20	CI

Chart GI Dynamics, Inc.

Duration

Period

More charts

Company Profile

GI Dynamics, Inc. is a medical device company. The Company designs and applies device and disease management solutions for the treatment of metabolic disease. The Company designs, develops, manufactures and markets medical devices for non-surgical approaches to treat type II diabetes and obesity. The Company's product, EndoBarrier, is an endoscopically-delivered device therapy, which is approved for the treatment of obese type II diabetes with body mass index (BMI) greater than or equal to 30 kilogram/square meter (kg/m2), or obese patients with BMI greater than or equal to 30 kg/m2 with greater than or equal to one comorbidities, or obese patients with BMI over 35 kg/m2. EndoBarrier is an incision-free, non-anatomy altering solution designed to specifically mimic the duodenal-jejunal exclusion created by gastric bypass surgery.

Sector

More about the company